LUND, Sweden, July 1, 2026
Hansa Biopharma AB has completed its €115 million exclusive licensing transaction with SERB Pharmaceuticals for the commercialization of Idefirix® (imlifidase) across Europe, the United Kingdom, Switzerland, Norway, Liechtenstein, Iceland, and the Middle East and North Africa (MENA), marking a major strategic milestone for the commercial-stage biopharmaceutical company. The transaction, finalized after receiving all required regulatory approvals, significantly strengthens Hansa Biopharma’s financial position while enabling the company to intensify preparations for the anticipated U.S. launch of imlifidase, subject to FDA approval.
Under the agreement, SERB Pharmaceuticals assumes responsibility for the development and commercialization of Idefirix in solid organ transplantation throughout the licensed territories. The agreement includes an upfront payment of €110 million and an additional €5 million milestone payment upon acceptance of the filing for full European Medicines Agency (EMA) approval of Idefirix. The partnership combines Hansa’s innovative immunology platform with SERB’s established expertise in rare diseases and specialty pharmaceuticals, aiming to expand patient access to this pioneering therapy for highly sensitized kidney transplant recipients.
Strategic Licensing Strengthens Global Commercialization
The completion of the licensing agreement represents a significant step in Hansa Biopharma’s global commercialization strategy. While Hansa retains its broader research and development focus, SERB Pharmaceuticals will now oversee commercialization activities for Idefirix across the licensed European and MENA territories. SERB brings more than 25 years of experience in rare diseases, rare medical emergencies, and specialty pharmaceuticals, supported by commercial operations in 18 countries and a portfolio exceeding 70 marketed products.
Hansa will continue supporting the regulatory transition by working with the European Medicines Agency to transfer the Marketing Authorization to SERB and assist in securing full regulatory approval based on positive post-authorization efficacy data. SERB will also assume responsibility for ongoing post-authorization studies and pediatric clinical development, ensuring continued regulatory compliance and long-term clinical evidence generation.
Advertisement
Idefirix Addresses Critical Unmet Need in Kidney Transplantation
Idefirix (imlifidase) is a first-in-class IgG antibody-cleaving enzyme therapy designed to rapidly eliminate circulating immunoglobulin G (IgG) antibodies within hours, enabling kidney transplantation in highly sensitized patients who otherwise face extremely limited transplant opportunities. The therapy currently holds conditional approval in Europe for desensitization treatment in adult kidney transplant candidates with positive crossmatch results against available deceased donors.
Highly sensitized patients often remain on transplant waiting lists for years because pre-existing antibodies prevent successful transplantation. By rapidly removing these antibodies, Idefirix creates new opportunities for transplantation while addressing a significant unmet medical need in end-stage renal disease. Hansa continues to advance additional clinical evidence supporting long-term efficacy and safety while expanding the scientific understanding of its proprietary IgG-cleaving enzyme platform.
Transaction Supports U.S. Launch and Pipeline Expansion
The licensing proceeds provide Hansa Biopharma with substantial financial flexibility as the company advances toward potential commercialization in the United States. Earlier this year, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for imlifidase, assigning a Prescription Drug User Fee Act (PDUFA) target action date of December 19, 2026. In addition to supporting U.S. launch preparations, the strengthened balance sheet enables continued investment in Hansa’s expanding immunology pipeline, including HNSA-5487, a next-generation IgG-cleaving molecule under development for Guillain-Barré Syndrome (GBS). By combining commercial expansion with continued innovation in transplantation, autoimmune diseases, and gene therapy, Hansa Biopharma continues strengthening its position as a leader in novel immunomodulatory therapies designed to address serious immune-mediated diseases worldwide.
Source: Hansa Biopharma press release
